Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage

The antiviral drug ribavirin (RBV) is widely used in combination with interferon (IFN) in the treatment of chronic hepatitis C virus (HCV) infection. A major side effect of RBV is a reversible hemolytic anemia. We have evaluated the in vitro effects of RBV on erythrocyte adenosine triphosphate (ATP) content and on hexosemonophosphate shunt (HMS). The ATP levels were significantly decreased in the presence of RBV and the HMS was increased, suggesting the presence of red cell susceptibility to oxidation. In vivo, we have studied the hematologic effects of treatment with RBV alone or in combination with IFN in 11 patients with chronic hepatitis C: 6 were treated with RBV (1,000‐1,200 mg/d) and 5 were treated with a combination of RBV and IFN (5 million U thrice weekly). Patients were studied at semi‐monthly intervals from 0 to day 60 of therapy. Both treatments were associated with a significant reduction in hemoglobin levels (steady state level at day 45) and a marked increase in absolute reticulocyte counts. Erythrocyte Na‐K pump activity was significantly diminished, whereas K‐Cl cotransport and its dithiotreitol‐sensitive fraction, malondialdehyde and methemoglobin levels were significantly increased. RBV‐treated patients showed an increase in aggregated band 3, which was associated with a significantly increased binding of autologous antibodies and complement C3 fragments indicating an erithrophagocytic removal by reticuloendothelial system.

[1]  O. Weiland,et al.  Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis. , 1999, Gastroenterology.

[2]  M. Grusch,et al.  Consequences of IMP dehydrogenase inhibition, and its relationship to cancer and apoptosis. , 1999, Current medicinal chemistry.

[3]  P. Couzigou,et al.  A randomized trial of ribavirin and interferon-α vs. interferon-α alone in patients with chronic hepatitis C who were non-responders to a previous treatment , 1999 .

[4]  P. Couzigou,et al.  A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, France. , 1999, Journal of hepatology.

[5]  E. Keeffe,et al.  Treatment strategies for chronic hepatitis C: Update since the 1997 National Institutes of Health Consensus Development Conference , 1999, Journal of gastroenterology and hepatology.

[6]  J. Hoefs,et al.  Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[7]  William M. Lee,et al.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[8]  P. Marcellin,et al.  Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus , 1998, The Lancet.

[9]  O. Olivieri,et al.  Decreased band 3 anion transport activity and band 3 clusterization in congenital dyserythropoietic anemia type II. , 1998, Experimental hematology.

[10]  P. Glue,et al.  Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine‐sensitive (es)‐nucleoside transporters , 1998, British journal of pharmacology.

[11]  G. Davis,et al.  Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial , 1997, Hepatology.

[12]  O. Platt,et al.  Reticulocyte hemoglobin: an integrated parameter for evaluation of erythropoietic activity. , 1997, American journal of clinical pathology.

[13]  K. Onodera,et al.  Functional assessment of proliferating hepatocytes stimulated by hepatic stimulatory substance in ascorbic acid biosynthetic enzyme‐deficient rats , 1997, Hepatology.

[14]  L. Hedstrom,et al.  Kinetic mechanism of human inosine 5'-monophosphate dehydrogenase type II: random addition of substrates and ordered release of products. , 1997, Biochemistry.

[15]  A. Bhalla,et al.  Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. , 1997, Gastroenterology.

[16]  P. Arese,et al.  Role of hemichrome binding to erythrocyte membrane in the generation of band-3 alterations in beta-thalassemia intermedia erythrocytes. , 1995, Blood.

[17]  N. Olivieri,et al.  Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo. , 1995, Blood.

[18]  M. Tong,et al.  Clinical outcomes after transfusion-associated hepatitis C. , 1995, The New England journal of medicine.

[19]  R Chirillo,et al.  Simultaneous measurement of reticulocyte and red blood cell indices in healthy subjects and patients with microcytic and macrocytic anemia. , 1995, Blood.

[20]  H. Simmonds,et al.  Effects of novel anti-viral adenosine analogues on the activity of S-adenosylhomocysteine hydrolase from human liver. , 1994, Biochemical pharmacology.

[21]  P. Marcellin,et al.  Treatment of chronic viral hepatitis. , 1994, Bailliere's clinical gastroenterology.

[22]  P. Arese,et al.  Binding of naturally occurring antibodies to oxidatively and nonoxidatively modified erythrocyte band 3. , 1994, Biochimica et biophysica acta.

[23]  P. Low,et al.  Characterization of the autologous antibodies that opsonize erythrocytes with clustered integral membrane proteins. , 1993, Blood.

[24]  L. De Franceschi,et al.  Effect of cell age and phenylhydrazine on the cation transport properties of rabbit erythrocytes , 1993, Journal of cellular physiology.

[25]  H. Lutz.  Naturally occurring anti-band 3 antibodies. , 1992, Transfusion medicine reviews.

[26]  P. Low,et al.  Isolation, characterization, and immunoprecipitation studies of immune complexes from membranes of beta-thalassemic erythrocytes. , 1992, Blood.

[27]  P. Low,et al.  Clustering of integral membrane proteins of the human erythrocyte membrane stimulates autologous IgG binding, complement deposition, and phagocytosis. , 1991, The Journal of biological chemistry.

[28]  J. Patterson,et al.  Molecular mechanisms of action of ribavirin. , 1990, Reviews of infectious diseases.

[29]  H. Mitsuya,et al.  Molecular targets for AIDS therapy. , 1990, Science.

[30]  K. Kikugawa,et al.  Binding of anti-band 3 autoantibody to oxidatively damaged erythrocytes. Formation of senescent antigen on erythrocyte surface by an oxidative mechanism. , 1990, The Journal of biological chemistry.

[31]  F. Bontemps,et al.  Mechanism of adenosine triphosphate catabolism induced by deoxyadenosine and by nucleoside analogues in adenosine deaminase-inhibited human erythrocytes. , 1989, Cancer research.

[32]  M. Haas,et al.  Stimulation of K-C1 cotransport in rat red cells by a hemolytic anemia-producing metabolite of dapsone. , 1989, The American journal of physiology.

[33]  P. Low,et al.  Isolation and characterization of the hemichrome-stabilized membrane protein aggregates from sickle erythrocytes. Major site of autologous antibody binding. , 1988, The Journal of biological chemistry.

[34]  H. Lutz,et al.  Naturally occurring anti-band-3 antibodies and complement together mediate phagocytosis of oxidatively stressed human erythrocytes. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[35]  J. Longstreth,et al.  Ribavirin disposition in high‐risk patients for acquired immunodeficiency syndrome , 1987, Clinical pharmacology and therapeutics.

[36]  T. Cosgriff,et al.  Hematological and bone marrow effects of ribavirin in rhesus monkeys. , 1984, Toxicology and applied pharmacology.

[37]  D. Carson,et al.  Adenosine kinase initiates the major route of ribavirin activation in a cultured human cell line. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[38]  T. Zimmerman,et al.  Metabolism of 5-amino-1-beta-D-ribofuranosylimidazole-4-carboxamide and related five-membered heterocycles to 5'-triphosphates in human blood and L5178Y cells. , 1978, Biochemical pharmacology.

[39]  J. Kaplan,et al.  International Committee for Standardization in Haematology: Recommended Methods for Red‐Cell Enzyme Analysis * , 1977, British journal of haematology.

[40]  S. Shohet,et al.  Lipid membrane peroxidation in beta-thalassemia major. , 1976, Blood.

[41]  P. Glue,et al.  The clinical pharmacology of ribavirin. , 1999, Seminars in liver disease.

[42]  P. Winch,et al.  Adaptation to malaria: The interaction of biology and culture , 1999 .

[43]  P. Marcellin,et al.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) , 1998, Lancet.

[44]  A. Sangchan.  Interferon Alfa-2b Alone or in Combination with Ribavin as Intial Treatment for Chronic Hepatitis C , 1998 .

[45]  D. Girelli,et al.  Oxidative damage and erythrocyte membrane transport abnormalities in thalassemias. , 1994, Blood.

[46]  J. Connor,et al.  The metabolism of ribavirin in erythrocytes and nucleated cells. , 1990, The International journal of biochemistry.

[47]  P. Arese,et al.  A simplified method for the pentose phosphate pathway assay in red cells. , 1982, The International journal of biochemistry.

[48]  G. Brewer.  Chapter 11 – Red Cell Metabolism and Function , 1970 .

[49]  A. Lajtha,et al.  Red Cell Metabolism and Function , 1970, Advances in Experimental Medicine and Biology.